Introduction:
The biosimilars market in Britain is experiencing significant growth in 2026, reflecting a global trend towards increased adoption of biosimilar products. According to recent statistics, the biosimilars market in Britain is projected to reach a value of £2 billion by the end of the year, with a compound annual growth rate of 10%. This growth is driven by factors such as the expiration of patents on biologic drugs and increasing demand for cost-effective healthcare solutions.
Top 10 Biosimilars Developers in Britain 2026:
1. Biocon Ltd.
Biocon Ltd. is a leading biosimilars developer in Britain, with a market share of 15%. The company has a strong portfolio of biosimilar products across various therapeutic areas, including oncology and autoimmune diseases.
2. Celltrion Inc.
Celltrion Inc. is another key player in the British biosimilars market, holding a market share of 12%. The company is known for its expertise in developing high-quality biosimilar products at competitive prices.
3. Samsung Bioepis
Samsung Bioepis is a major biosimilars developer in Britain, with a market share of 10%. The company has a robust pipeline of biosimilar products and a strong presence in the global biosimilars market.
4. Sandoz
Sandoz is a subsidiary of Novartis and a prominent player in the British biosimilars market, with a market share of 8%. The company offers a wide range of biosimilar products and has a strong track record of quality and reliability.
5. Pfizer Inc.
Pfizer Inc. is a leading pharmaceutical company with a significant presence in the biosimilars market in Britain, holding a market share of 7%. The company’s biosimilar portfolio includes products for rheumatoid arthritis and other autoimmune diseases.
6. Amgen Inc.
Amgen Inc. is a key player in the British biosimilars market, with a market share of 6%. The company is known for its innovative approach to biosimilar development and its commitment to quality and patient safety.
7. Teva Pharmaceutical Industries Ltd.
Teva Pharmaceutical Industries Ltd. is a major biosimilars developer in Britain, with a market share of 5%. The company has a diverse portfolio of biosimilar products and a strong presence in the global biosimilars market.
8. Mylan N.V.
Mylan N.V. is a prominent player in the British biosimilars market, with a market share of 4%. The company is known for its focus on accessibility and affordability of biosimilar products, making them more widely available to patients.
9. Boehringer Ingelheim
Boehringer Ingelheim is a leading biosimilars developer in Britain, with a market share of 3%. The company has a strong track record of innovation in biosimilar development and a commitment to improving patient outcomes.
10. Biogen Inc.
Biogen Inc. is a key player in the British biosimilars market, with a market share of 2%. The company is known for its expertise in developing biosimilar products for neurological disorders and other complex diseases.
Insights:
The biosimilars market in Britain is expected to continue its growth trajectory in the coming years, driven by factors such as increasing demand for cost-effective healthcare solutions and the expiration of patents on biologic drugs. By 2030, the biosimilars market in Britain is projected to reach a value of £4 billion, with a compound annual growth rate of 12%. Key players in the market will need to focus on innovation, quality, and affordability to maintain their competitive edge and meet the growing demand for biosimilar products.
Related Analysis: View Previous Industry Report
